Universal Time: 10:53  |  Local Time: 10:53 (0h GMT)
Select your timezone:
Room: E-Poster Hall

P-14.14 Durable effect of beta cell replacement therapy on improvement in blood glucose control and prevention of progression of secondary diabetic complications in nonuremic patients with type 1 diabetes mellitus and problematic hypoglycemia

Piotr J Bachul, United States

Research Fellow
Surgery
University of Chicago

Recommended Reading Websites

Piotr Witkowski Labolatory

Abstract

Durable effect of beta cell replacement therapy on improvement in blood glucose control and prevention of progression of secondary diabetic complications in nonuremic patients with type 1 diabetes mellitus and problematic hypoglycemia

Piotr J. Bachul1, Peter Borek1, Roi Anteby2, Lindsay Basto1, Laurencia Perea1, Karolina Golab1, Ling-Jia Wang1, Martin Tibudan1, Angelica Perez-Gutierrez1, Aaron C. Lucander1, John Fung1, Piotr Witkowski1.

1Surgery, University of Chicago, Chicago, IL, United States; 2Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Introduction: Beta cell replacement therapy in form of pancreas or islet transplantation is the only effective treatment for patients suffering from hypoglycemic unawareness despite intensive insulin treatment. Transplant provide endogenous insulin allowing for physiologic optimal blood glucose control.
Materials and Methods: 13 consecutive nonuremic patients with “brittle” type 1 diabetes (T1DM) received 28 islet transplants (up to 3 islet infusions) and 4 of them subsequently pancreas transplantation to extend benefit of insulin independence. Thymoglobulin was used during first islet transplant and basiliximab prior to subsequent islet and pancreas transplants for induction, whereas tacrolimus and mycophenolate for maintenance immunosuppression. Patient received Reparixin, etarnecept or no anti-inflammatory therapy in peritransplant period.
Results: Three patients developed donor specific antibodies (DSAs) with antibody mediated rejection and 1 severe cytokine release syndrome and 1 bleeding, which compromised islet graft function. Overall 1, 2, 3 and 5 year insulin independence rate after first islet transplantation was 11/13 (85%), 11/13 (85%) and 8/13 (61%), 6/13 (46%), respectively. Four patients received pancreas tx after median 4.5 years (3.5 - 6.5) increasing 5 and 6 year insulin independence rate to 61.5% (8/13) and 60% (6/10), respectively. Currently, 61.5% (8/13)  are still off insulin with median follow up 6 years (5.3 - 7.6) and 2 more with partial islet function with A1c of 5.5% and 6.6% leading to 10/13 (77%) patients without severe hypoglycemic episodes and hypoglycemia unawareness. Remaining 3 patients dropped the study due to social reasons right after their first or second islet transplant, or one due to leukemia. Secondary diabetic complications such as the diabetic neuropathy remained stable but retinopathy improved in 4/13 patients (30%). None of the patients experienced any of the cardiovascular events. One patient with creatinine 1.55 mg/ml (GFR = 59) received kidney together with pancreas transplantation. 
Conclusion: Beta cell replacement therapy in form of islet and subsequent pancreas transplantation has proven its long term efficacy in restoring normoglycemia and alleviating the immediate burden of hypoglycemic unawareness as well as preventing progression of secondary complications.

Comments

There are no comments yet...

WebApp Sponsor

© 2020 TTS 2020